[Special Stock] Boditech Med Anticipated to Enter Animal Diagnostics Market... "Finalizing US Contract"

Bodytech Med is showing strong performance. This is interpreted as being influenced by securities firms' analysis that the mid- to long-term growth momentum due to entry into the animal diagnostics market remains valid.

As of 9:38 AM on the 24th, Bodytech Med was trading at 16,280 KRW, up 480 KRW (3.04%) compared to the previous trading day.

Bodytech Med's third-quarter sales and operating profit were 37.6 billion KRW and 8.8 billion KRW, respectively, marking increases of 7.8% and 0.6% compared to the same period last year. Jiwoo Baek, a researcher at Shinhan Investment Corp., explained, "Sales in the Middle East and North Africa exceeded 10 billion KRW, reaching an all-time high."

He added, "There was also a sharp growth in point-of-care diagnostic sales mainly in Iraq and Egypt," and analyzed, "Recently, CE certification was obtained for 14 types of diagnostic devices and 142 types of diagnostic kits under the European Conformity standards, and molecular diagnostics and drug diagnostics products are also preparing for CE approval. Currently, sales to Europe account for more than 20%, and this certification is expected to expand European sales."

He explained, "The full-scale supply of chronic disease monitoring diagnostic products in China in the first half of next year and entry into the animal diagnostics market are the biggest new growth drivers," emphasizing, "It is necessary to pay attention to the actual contribution to sales."

Researcher Baek emphasized, "Although discussions on supplying animal diagnostic products to a U.S. company were prolonged, causing increased stock price volatility in the fourth quarter, the decision was made to use the existing OEM (Original Equipment Manufacturer) supply method instead of utilizing our own sales network, and the contract is now entering the finalization stage."

This content was produced with the assistance of AI translation services.